REPRODUKTIV VA POSTMENOPAUZA YOSHIDAGI AYOLLARDA ENDOMETRIYAL SARATONNING XAVF OMILLARI VA KLINIK VA EPIDEMIOLOGIK XUSUSIYATLARINI TAHLIL QILISH
Keywords:
endometriyal saraton, reproduktiv yosh, postmenopauza, semizlik, gormonal disbalans, xavf omillari, epidemiologiyaAbstract
Endometriyal saraton — ayollar reproduktiv tizimining eng ko‘p uchraydigan malign o‘smalaridan biri bo‘lib, uning rivojlanishi asosan gormonal muvozanat, metabolik buzilishlar va reproduktiv tarix bilan bog‘liq. Ushbu maqolada reproduktiv hamda postmenopauza yoshidagi ayollarda endometriyal saratonning xavf omillari, epidemiologik va klinik xususiyatlari xalqaro ilmiy adabiyotlar asosida tahlil qilindi. Tadqiqotlar shuni ko‘rsatadiki, semizlik, giperglikemiya, polikistik tuxumdon sindromi, nulliparitet, erta menarxe va kech menopause, shuningdek, faqat estrogen bilan olib borilgan gormonterapiya xavf omillarining asosiy qismini tashkil qiladi. Himoya qiluvchi omillarga esa ko‘p tug‘ish, laktatsiya, sog‘lom turmush tarzi va estrogen-progesteron muvozanatini ta’minlash kiradi. Ushbu maqolaning maqsadi — endometriyal saratonning oldini olish va erta tashxis qo‘yish uchun muhim bo‘lgan omillarni aniqlashdan iborat.
References
Morice P., Leary A., Creutzberg C., Abu-Rustum N., Darai E. Endometrial cancer. The Lancet. 2016;387(10023):1094–1108.
DOI: 10.1016/S0140-6736(15)00130-0
Concin N., Matias-Guiu X., Vergote I., et al. ESGO/ESTRO/ESP Guidelines for the Management of Patients with Endometrial Carcinoma. International Journal of Gynecological Cancer. 2021;31(1):12–39.
DOI: 10.1136/ijgc-2020-002230
Nishimura R., Hussein Y., Abu-Rustum N. Updates in FIGO staging of endometrial cancer. International Journal of Gynecology & Obstetrics. 2023;160(S1):17–24.
DOI: 10.1002/ijgo.14843
Bell D.W., Ellenson L.H. Molecular genetics of endometrial carcinoma. Annual Review of Pathology: Mechanisms of Disease. 2019;14:339–367. DOI: 10.1146/annurev-pathmechdis-012418-012807
Getz G., et al. (TCGA Research Network). Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73. DOI: 10.1038/nature12113
Clement P.B., Young R.H. Non-endometrioid carcinomas of the uterine corpus: A review of their pathology. Modern Pathology. 2019;32(1):64–82. DOI: 10.1038/s41379-018-0114-x
Bokhman J.V. Two pathogenetic types of endometrial carcinoma. Gynecologic Oncology. 1983;15(1):10–17. DOI: 10.1016/0090-8258(83)90111-7
Creutzberg C.L., et al. Adjuvant chemotherapy and radiotherapy in endometrial cancer. Journal of Clinical Oncology. 2011;29(13):1686–1693. DOI: 10.1200/JCO.2010.32.1048
Miller K.D., et al. Cancer statistics, 2023. CA: A Cancer Journal for Clinicians. 2023;73(1):17–48. DOI: 10.3322/caac.21763
Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2020. CA: A Cancer Journal for Clinicians. 2021;71(3):209–249.
DOI: 10.3322/caac.21660
NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms. Version 2024. National Comprehensive Cancer Network. URL: https://www.nccn.org (доступ свободный)
WHO Classification of Female Genital Tumours. 5th edition. World Health Organization; IARC Press, Lyon; 2020. ISBN: 978-92-832-4502-6
Vaughan L., et al. Endometrial cancer in premenopausal women: risk factors and clinical characteristics. Gynecologic Oncology. 2020;159(2):484–490. DOI: 10.1016/j.ygyno.2020.08.021
Emons G., Beckmann M.W., et al. New insights into endocrine-related endometrial carcinogenesis. Nature Reviews Endocrinology. 2022;18:445–458.
DOI: 10.1038/s41574-022-00689-w